Sanofi launches injectable polio vaccine in India

Sanofi headquarters in Lyon, France. Photo: Reuters
Sanofi Pasteur, the vaccines division of French pharmaceutical major Sanofi, announced today the launch of ShanIPV, an injectable inactivated polio (IPV) vaccine.

The vaccine will be manufactured by Hyderabad-based Shantha Biotechnics Private Limited, an affiliate of Sanofi Pasteur.

Shantha will provide 2.3 million doses of ShanIPV in 2015, and 9 million in 2016 to Unicef for India's needs. The company plans to produce a total of over 10 million doses in 2016 with additional increases planned in subsequent years, the company said.

Injectable IPV is a part of WHO led initiative to move from oral administration of polio vaccine to injectables.

"Today, we are proud to further strengthen our commitment towards disease prevention and support the Indian Government's universal immunisation programme, including polio eradication. With the introduction of IPV in the immunisation schedule, our company is playing a key role in achieving the goal of a polio-free world,"said Shailesh Ayyangar, managing director- India and vice president-South Asia,of Sanofi.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel